EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Full year performance expected to be in-line with management expectations

16th Jun 2021

Appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and broker, N+1 Singer.

7th Jun 2021

Presentation to institutional investors by Julian Baines and Mike Salter.

Launch of Restricted Offer

EKF Diagnostics provides a further update regarding its forthcoming changes to the board of directors of the Company and its planned, final performance related payments to the Company’s Chief Executive Officer and Finance Director. 

19th May 2021

Strong trading continues into Q2, upgrading full year expectations. Growth Plans & Managed Succession

18th May 2021

Trellus Health plc proposed placing, subscription and restricted offer.

Further to the announcement on 23 April 2021.

30th Apr 2021

Adam Reynolds, Non-Executive Director, has sold a total of 500,000 ordinary shares.

29th Apr 2021